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A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF)
support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998
and August 2001, 50 patients were registered in this phase II study. Cisplatin (20mgm
2) and ifosfamide (1.5gm
2) were
administered on days 1–4 and irinotecan (60mgm
2) was given on days 1, 8, and 15, respectively. This regimen was repeated every
4 weeks. rhG-CSF was administered subcutaneously at a dose of 50mgm
2 on days 5–18 except on the days of irinotecan
treatment. In total, 49 patients were assessable for toxicity and response and 50 for survival. In all, 33, patients (67.3%; 95%
confidence interval 57.4–77.2%) achieved an objective response. The median response duration was 192 days and the median time
to progression for 49 patients was 170 days. The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and
30.7%, respectively. Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively. In
conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of
stage IIIB or IV NSCLC with acceptable toxicities.
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In the 1990s, a number of new chemotherapeutic agents such as the
taxanes, vinorelbine, gemcitabine, and irinotecan were introduced
into the management of advanced non-small-cell lung cancer
(NSCLC). Irinotecan is a semisynthetic water-soluble derivative of
camptothecin. Its mechanism of action is the inhibition of DNA
topoisomerase I through the formation of topoisomerase I–DNA
cleavable complexes (Hsiang et al, 1985; Hertzberg et al, 1989). A
phase II study showed a high clinical efficacy of irinotecan in
previously untreated NSCLC, with patients responding at a rate of
32% (Fukuoka et al, 1992). In a phase II study of irinotecan and
cisplatin in patients with stage IIIB or IV disease, the response rate
was 52% and the median survival time was 52 weeks (Masuda et al,
1998). In order to develop a more effective regimen, studies have
been conducted in which the dose intensity of irinotecan and/or
cisplatin has been increased (Masuda et al, 1994; Kobayashi et al,
1998; Ueoka et al, 2001), and in which various triplet-drug
combination therapies using irinotecan, cisplatin, and another
drug have been explored (Shinkai et al, 1994). Ifosfamide is an
analogue of cyclophosphamide and shows significant activity
against NSCLC (Costanza et al, 1978).
In the light of these previous studies, we conducted a phase I
study of escalating dose of irinotecan combined with a fixed
schedule of cisplatin and ifosfamide with recombinant human
granulocyte colony stimulating factor (rhG-CSF) support in
advanced NSCLC (Fujita et al, 1999). The combination of cisplatin
and ifosfamide at respective doses of 20mgm
2 and 1.5gm
2 was
administered on days 1–4, and irinotecan was given on days 1, 8,
and 15, starting at 40mgm
2 and increased in 10mgm
2
increments. The dose of 60mgm
2 was defined as the recom-
mended dose of irinotecan for the subsequent phase II study. In
chemotherapy-naive patients, a very promising response rate of
65.7% and a median survival time of 513 days were obtained in this
trial.
Based on these findings, we performed a phase II study in order
to determine the antitumour activity and toxicity of a combination
of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for
the treatment of previously untreated patients with stage IIIB and
IV NSCLC.
PATIENTS AND METHODS
Patient selection
Patients were enrolled in the study if they met all of the following
eligibility criteria and did not meet any of the exclusion criteria:
(1) histologically or cytologically confirmed advanced NSCLC
(stage IIIB or IV), (2) no prior chemotherapy, (3) a life expectancy
of at least 3 months, (4) a performance status (PS) of 0–1 on the
ECOG scale, (5) between 15 and 75 years of age, (6) presence of
bidimensionally measurable disease, (7) adequate bone marrow
reserve (haemoglobin X9gdl
1, leucocyte count X4000mm
3,
platelet count X100000mm
3), renal function (serum creatinine
o1.5mgdl
1), and liver function (AST, ALT o twice the upper
limit of normal, and serum total bilirubin o 1.5mgdl
1), and (8) Received 1 July 2002; revised 4 June 2003; accepted 29 June 2003
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lthe patient providing written informed consent for participation.
The protocol was approved by an ethics review board at the
Minami-ichijo Hospital.
Exclusion criteria were as follows: (1) severe concurrent medical
conditions, (2) pregnant or nursing mothers, (3) active concomi-
tant malignancy, (4) active uncontrolled infection, (5) intestinal
paralysis and obstruction, (6) interstitial pneumonia or pulmonary
fibrosis, and (7) large amount of ascites and/or pleural effusion.
Evaluation
Mandatory preregistration evaluations included a baseline history,
physical examination, chest X-ray, chest computed tomography
(CT), bronchoscopy, head magnetic resonance imaging or CT,
abdominal CT or ultrasonography, bone scintigraphy, complete
blood cell counts (CBC) with differential, routine chemistry
profiles, urinalysis, ECG, and pulmonary function test. During
the chemotherapy courses, all patients were reviewed daily for
symptoms of toxicity and underwent clinical examination.
Complete blood cell count, including differential, was performed
at least twice weekly. Chest X-ray, routine chemistry profiles, and
urinalysis were performed at least once weekly. Tumour responses
were evaluated after every course on measurable lesions deter-
mined before registration by repeating the appropriate radio-
graphic studies. WHO evaluation criteria were used for efficacy
analysis (World Health Organization, 1979). Toxicities were
graded according to common toxicity criteria of the Eastern
Cooperative Oncology Group (ECOG) (Oken et al, 1982).
Treatment design
Ifosfamide at a dose of 1.5gm
2 was diluted in 500ml of 5%
glucose solution and given over a period of 2h as an i.v. infusion
followed by an i.v. infusion of cisplatin at a dose of 20mgm
2
diluted in 100ml of 0.9% saline solution over 30min on days 1–4.
Irinotecan at a dose of 60mgm
2 was dissolved in 250ml of 0.9%
saline solution and infused over a period of 90min on days 1, 8,
and 15. These dose and treatment schedules were designed on the
basis of our phase I study in patients with advanced NSCLC (Fujita
et al, 1999). rhG-CSF was administered subcutaneously at a dose of
50gm
2 on days 5–18 except on the days of irinotecan treatment.
All the patients received azasetron 10mg and dexamethasone
32mg intravenously on days 1–4 and azasetron only on days 8 and
15 before the irinotecan infusion. Mesna was given intravenously
at 20% of the dose of ifosfamide at 0, 4, and 8h after the
administration of ifosfamide. Antidiarrhoeal drugs were not used
prophylactically. If grade 2 or worse diarrhoea was observed, a
daily dose of 7.5g Hange-shasinto (a Kampo medicine) divided
into three portions was given. Hange-shasinto is an antio-
diarrhoeal agent with no inhibitory effect on intestinal motility.
The dose levels and treatment schedule were modified in order
to avoid severe toxicity. Irinotecan was administered on days 8 and
15 when all of the following three conditions were met on the day
of treatment: leucocyte count X2000mm
3, platelet count
X50000mm
3, and no grade 3 or worse diarrhoea. Cycles were
repeated every 4 weeks if the leucocyte count was X4000mm
3 or
the platelet count was X100000mm
3. The dose of irinotecan for
the subsequent course was reduced by 10mgm
2 if the leucocyte
count was o1000mm
3, or if the platelet count was
o25000mm
3, and if irinotecan was omitted on days 8 and/or
15 due to toxicity. If grade 4 diarrhoea occurred, the dose of
irinotecan for the next course was reduced by 10mgm
2. Dose
delays of less than 1 week were permitted and the treatment was
continued at the same doses after recovery from toxicity. If
recovery from toxicity took more than 1 week but less than 2
weeks, the dose of irinotecan was reduced by 10mgm
2. Patients
were excluded from the study if recovery took longer than 2 weeks.
Patients who responded to treatment could continue therapy
according to the above dose modification procedure until disease
progression or the development of unacceptable toxicity.
Statistical analysis
The Kaplan–Meier method was used to estimate the response
duration, time to progression, and overall survival. Time to
progression and survival were calculated from the first day of
chemotherapy. The primary end point of this study was the
assessment of objective response rate. We assumed that a response
rate of 70% would be potentially useful, while a rate of 50% would
be the lower limit of interest. These response rates were based on
the results of our previous phase I study in the subset of patients
treated with the same dose of irinotecan and the phase II study of
cisplatin and irinotecan (Masuda et al, 1998), respectively. Our
design had a statistical power of greater than 80%, with a less than
5% error. In all, 50 patients were required in this phase II study,
assuming that less than 20% of the patients entered would not be
assessable for response.
RESULTS
Patient characteristics
Between June 1998 and August 2001, 50 patients were registered in
this phase II study. One patient was withdrawn from the study on
that day because of brain infarction on day 4 in the first course.
Therefore, 49 patients were assessable for toxicity and response.
Patient characteristics are listed in Table 1. There were 31 men and
19 women with a median age of 57 years (range 38–71 years).
Seven patients had a PS of 0, and 43 patients a PS of 1. Clinical
stage was IIIB in 16 patients and IV in 34. Of the 34 patients with
stage IV disease, the sites of metastasis included the lung in 10,
brain in 14, bone in 10, liver in two, and adrenal in four. Of the17
patients with carcinomatous pleurisy, 14 had stage IV and three
Table 1 Patient characteristics
Characteristics No of patients
Sex
Male 31
Female 19
Age (years)
Median 57
Range 38–71
Performance status (ECOG)
07
14 3
Histology
Adenocarcinoma 40
Squamous cell carcinoma 8
Large cell carcinoma 2
Stage
IIIB 16
IV 34
Site of metastasis
Lung 10
Brain 14
Bone 10
Liver 2
Adrenal 4
Abdominal LN 2
Carcinomatous pleurisy 17
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adenocarcinoma.
Treatment delivery
Of the 50 patients, 39 received three or more courses of
chemotherapy. One patient was removed from the study because
of brain infarction on day 4 of the first course. In 10 patients,
chemotherapy was discontinued after two courses due to a
complete abscence of efficacy. The mean number of chemotherapy
courses was 4.3 in 50 patients.
In 11 patients, irinotecan treatment was omitted on days 8 and/
or 15 of the first course because of toxicity. The reasons for
cessation of irinotecan treatment on days 8 and/or 15 at each
course are listed in Table 2, which shows that the most common
reasons for cessation were leucopenia and/or thrombocytopenia.
At each course, the percentage of the projected irinotecan dose
actually administered was 90.0% at the first course, 89.5% at the
second course, and 78.5% at the third course. Only 17 patients
received three or more courses of chemotherapy without dose
modification.
Response and survival
Of the 50 patients, 49 were assessable for response. No patient
showed a complete response, but 33 patients achieved a partial
response (PR), 14 no change, and one patient had progressive
disease. The overall response rate was 67.3% (95% confidence
interval (CI) 57.4–77.2%). The response rates for stage IIIB and IV
were 62.5% (10 of 16 patients) and 69.7% (23 of 33 patients),
respectively. The median time to remission was 52 days and the
median response duration was 192 days. The median time to
progression for 49 patients was 170 days. Of the 11 patients
assessable for response to brain metastases, seven achieved PR.
The combined treatment was also effective in 11 of 17 patients with
carcinomatous pleurisy. Of 16 patients with stage IIIB disease,
thoracic radiotherapy was performed on four patients in remission
after three or more courses of chemotherapy. After the disconti-
nuation of this study, 38 patients were entered in the two different
phase I studies of carboplatin, docetaxel, and irinotecan with rhG-
CSF support (Fujita et al, 2000b, 2002).
All patients were assessed for survival, on the basis of intent to
treat. With a median follow-up of 923 days, 17 patients were still
alive. The median survival time was 540 days (95% CI, 522–558
days) with 1- and 2-year survival rates of 63.5 and 30.7%,
respectively (Figure 1). According to clinical stage, the median
survival times were 537 days in stage IIIB and 549 days in stage IV.
The 1- and 2-year survival rates in patients with stage IIIB disease
were 74.5 and 44.7%, compared with 58.4 and 28.9%, respectively,
in patients with stage IV disease (Figure 2).
Toxicity
Toxicities occurring during the three courses are listed in Table 3.
The most significant toxicity was myelosuppression. Details of
haematological toxicity at each course are listed in Table 4. Grade 3
and 4 leucopenia occurred in 22 and six patients, respectively. The
leucocyte nadir occurred at around day 15 during each of the three
courses. Grade 4 neutropenia developed in 20 patients, but it never
lasted for more than 5 days except in one patient. Eight patients
experienced neutropenic fever, but no patients suffered from
neutropenic sepsis. Nine and 10 patients experienced grade 3 and 4
thrombocytopenia, respectively. Eight patients required platelet
transfusion. Anaemia was prominent and 26 patients required red
Table 2 Dose modification
Reasons for cessation of irinotecan treatment
Course No. of patients On Day 8 On Day 15 Dose intensity
First 50 Total 4 Total 12 90.0
Brain infarction 1 Brain infarction 1
Infection 1 Pneumonitis 1
Thrombocytopenia 1 Diarrhoea 1
Diarrhoea 1 Leucopenia 6
Thrombocytopenia 2
Leucopenia and Thrombocytopenia 1
Second 49 Total 0 Total 12 89.5
1 Infection 1
Leucopenia 6
Thrombocytopenia 3
Leucopenia and Thrombocytopenia 1
Third 39 Total 1 Total 19 78.5
Leucopenia Leucopenia 5
Thrombocytopenia 7
Leucopenia and Thrombocytopenia 7
200 0 400 600 800 1000
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Figure 1 Overall survival of 50 patients.
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lblood cell transfusion. Increase in the number of the chemother-
apy course was associated with severity of myelotoxicity. Nausea
and anorexia of grade 2 or worse were observed in most patients.
Diarrhoea worse than grade 2 was observed in three patients, but
the symptoms proved to be transient. In all, 25 patients showed
elevation of serum transaminase, although this condition was
transient and not significantly severe. Pneumonitis developed in
one patient and was improved with corticosteroid treatment. There
were no treatment-related deaths.
DISCUSSION
As a single agent, irinotecan results in a significant response rate in
previously untreated NSCLC patients, and with the combination of
irinotecan and cisplatin, an encouraging response rate of 52% has
been found (Masuda et al, 1998). In the two Japanese multi-
institutional randomised trials (Masuda et al, 1999; Niho et al,
1999), cisplatin plus irinotecan significantly improved survival
compared to cisplatin plus vindesine in patients with metastatic
NSCLC, as determined by multivariate analysis (Fukuoka et al,
2000). The present study was designed to test whether the
combination of cisplatin and irinotecan with ifosfamide can
develop a more effective regimen. With prophylactic administra-
tion of rhG-CSF, from May 1994 to June 1995, we conducted a
phase I study of irinotecan on days 1, 8, and 15 combined with a
fixed schedule of cisplatin and ifosfamide and determined the
200 0 400 600 800 1000
(days)
1200 1400
0
20
40
60
80
100
(
%
)
Stage IIIB (n=16)
Stage IV   (n=34)
Figure 2 Over all survival according to clinical stage.
Table 3 Toxicity
CTC grade Xgrade 3
Toxicity 01234 N o o f patients %
Haematological
Leucopenia 2 7 12 22 6 28 57.1
Neutropenia 2 10 6 11 20 31 63.3
Thrombocytopenia 17 3 10 9 10 19 38.8
Anaemia 1 4 27 17 17 34.7
Renal
BUN 24 22 3 0 0 0 0.0
Creatinine 49 0000 0 0 . 0
Haematuria 20 29 0 0 0 0 0.0
Liver
A S T 2 4 2 2210 1 2 . 0
A L T 2 4 2 1310 1 2 . 0
Bilirubin 49 0000 0 0 . 0
Gastrointestinal
Nausea 7 6 9 27 27 55.1
Anorexia 7 4 9 29 29 59.2
Vomiting 17 14 18 0 0 0 0.0
Diarrhoea 39 3403 3 6 . 1
Ulcer 00100 0 0 . 0
Pulmonary
Pneumonitis 00100 0 0 . 0
Cardiovascular
Cardiac-ischaemia 00010 1 2 . 0
Table 4 Haematological toxicity
First course Second course Third course
Leucopenia
Median nadir (10
3mm
3) 2.7 2.9 1.9
Range 0.3–5.5 0.6–5.1 0.5–5.1
Day nadir 15.0 15.0 15.0
Neutropenia
Median nadir (10
3mm
3) 1.3 1.5 0.8
Range 0.0–3.8 0.1–3.7 0.0–3.1
Day nadir 15.0 15.0 15.0
Thrombocytopenia
Median nadir (10
3mm
3) 12.6 10.9 6.4
Range 2.9–27.0 2.5-21.3 0.9–19.9
Day nadir 15.0 15.0 15.0
No. of patients transfused 1 0 7
Anaemia
Median nadir (gdl
1) 10.0 9.1 8.3
Range 7.7–12.5 7.3–11.6 7.0–11.1
No. of patients transfused 5 10 20
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lrecommended dose of irinotecan as 60mgm
2 for the subsequent
phase II study (Fujita et al, 1999).
The current phase II study demonstrates an encouraging
response rate of 67.3% comparable to the previously conducted
phase I study. There was no significant difference in the response
rate according to clinical stage. The response rate was also high in
patients with cerebral metastasis (Fujita et al, 2000a) and findings
such as disappearance of pleural effusion, negative cytology, and
improvement of pleural thickening were obtained in 11 of 17
patients with carcinomatous pleurisy (Fujita et al, 2001).
The median survival time and 1- and 2-year survival rates in all
patients were 540 days, 63.5 and 30.7%, respectively, and these
results were considered satisfactory. According to clinical stage,
the 1- and 2-year survival rates in patients with stage IIIB disease
were 74.5 and 44.7%, compared with 58.4 and 28.9%, respectively,
in patients with stage IV disease. The survival time obtained in the
current study is in the upper range of reported trials of
combination chemotherapy for NSCLC. However, due to patient’s
selection, it is difficult to reach valid conclusions regarding the
most effective chemotherapy based only on the historical results.
Recently, new drugs have demonstrated satisfactory activity as
second-line treatment in patients with NSCLC. After discontinua-
tion in the present study, 38 patients were registered into the two
different phase I studies of carboplatin, docetaxel, and irinotecan
with rhG-CSF support (Fujita et al, 2000b; 2002). Both these phase
I studies demonstrated an encouraging response rate in patients
with prior chemotherapy. The effect of such a second-line
chemotherapy on the results of this trial is unclear. However, the
role of a second-line chemotherapy should be taken into
consideration.
Grade 3 or 4 neutropenia developed in 63.3% of the patients in
the present trial. The severity of neutropenia was not completely
eliminated by rhG-CSF support. However, grade 4 neutropenia
lasting more than 5 days occurred in only one patient. The
availability of rhG-CSF apparently made it possible to reduce the
duration of neutropenia. Grade 3 or 4 thrombocytopenia occurred
in 38.8% of the patients in this trial. Only 17 patients received three
or more courses of chemotherapy without dose modification.
Haematological toxicity was severe despite the dose modification.
Three patients experienced grade 4 diarrhoea, were treated with
Hange-shasinto, and showed improvement.
In conclusion, the combination of cisplatin, ifosfamide, and
irinotecan with rhG-CSF support was highly effective for the
treatment of stage IIIB or IV NSCLC. Haematological toxicity was
prominent but manageable. Phase III trials are required to
determine whether this combination of three drugs with rhG-
CSF support will improve the response rate and survival in
previously untreated NSCLC patients.
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